Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
Health & Biotech
LTR Pharma inks national pharmacy distribution deal for its ED therapy
News
Closing Bell: Iron ore miners hammered, but Trump’s Canada tariffs boost uranium stocks
Health & Biotech
Health Check: We’ll see you in court and you bladder believe it, says Pacific Edge after unfavourable US ruling
Health & Biotech
LTR Pharma inks deal with men’s health provider for ED therapy
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Stockhead TV
Break it Down: Quick access to quick ED fix from LTR Pharma
Health & Biotech
LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment
Health & Biotech
Health Check: The robots are taking over biotech stock selection
Health & Biotech
Renerve all set to become only the second nerve-repair stock on the ASX
Health & Biotech
LTR Pharma joins with leading men’s health group to launch telehealth platform
Health & Biotech
Health Check: It’s a small world after all for global microcap index additions LTR Pharma and EZZ Life Science
Health & Biotech
ASX Quarterly Health Wrap: Lift-off for ED nasal spray and record users for pregnancy-monitoring platform
Health & Biotech
LTR Pharma’s ED treatment SPONTAN outperforms with 470% faster absorption
Health & Biotech
Health Check: Thirsty Chimeric goes to the well for funding top-up
Health & Biotech
ASX stocks leading clinical trials in Australia
Health & Biotech
Bio Curious: Nerve repair house plans to break the IPO drought
Health & Biotech
